Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
Total Valuation
Dogwood Therapeutics has a market cap or net worth of $70.48M. The enterprise value is -$2.33M.
Market Cap$70.48M
Enterprise Value-$2.33M
Share Statistics
Dogwood Therapeutics has 33,401,554 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,401,554
Owned by Insiders74.08%
Owned by Institutions<0.01%
Financial Efficiency
Dogwood Therapeutics’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -32.09%.
Return on Equity (ROE)-0.46
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-32.09%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee0.00
Profits Per Employee-2.85M
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dogwood Therapeutics is ―. Dogwood Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.46
Price to Fair Value0.46
Price to FCF-2.19
Price to Operating Cash Flow-1.96
PEG Ratio0.02
Income Statement
In the last 12 months, Dogwood Therapeutics had revenue of 0.00 and earned -34.26M in profits. Earnings per share was -4.32.
Revenue0.00
Gross Profit0.00
Operating Income-27.97M
Pretax Income-34.04M
Net Income-34.26M
EBITDA-27.97M
Earnings Per Share (EPS)-4.32
Cash Flow
In the last 12 months, operating cash flow was -15.62M and capital expenditures 4.00, giving a free cash flow of -15.62M billion.
Operating Cash Flow-15.62M
Free Cash Flow-15.62M
Free Cash Flow per Share-0.47
Dividends & Yields
Dogwood Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.43
52-Week Price Change-47.90%
50-Day Moving Average2.84
200-Day Moving Average4.61
Relative Strength Index (RSI)37.75
Average Volume (3m)1.54M
Important Dates
Dogwood Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateApr 6, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Dogwood Therapeutics as a current ratio of 2.76, with Debt / Equity ratio of 0.22%
Current Ratio2.76
Quick Ratio2.76
Debt to Market Cap0.00
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dogwood Therapeutics has paid 221.10K in taxes.
Income Tax221.10K
Effective Tax Rate>-0.01
Enterprise Valuation
Dogwood Therapeutics EV to EBITDA ratio is -1.00, with an EV/FCF ratio of -1.78.
EV to Sales0.00
EV to EBITDA-1.00
EV to Free Cash Flow-1.78
EV to Operating Cash Flow-1.78
Balance Sheet
Dogwood Therapeutics has $6.52M in cash and marketable securities with $162.60K in debt, giving a net cash position of $6.36M billion.
Cash & Marketable Securities$6.52M
Total Debt$162.60K
Net Cash$6.36M
Net Cash Per Share$0.19
Tangible Book Value Per Share-$0.79
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Dogwood Therapeutics is $13.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.50
Price Target Upside328.57% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-295.27%